Metformin has been prescribed for type 2 diabetes since the 1990s. It’s one of the most studied drugs in the world, it costs almost nothing as a generic, and it’s on the World Health Organization’s list of essential medicines. It’s also quietly become one of the more interesting drugs in aging research.

Here’s what it actually does and what the conversation around off-label use is about.

How metformin works

Metformin is not insulin. It doesn’t stimulate the pancreas to release more insulin. Instead, it works primarily in the liver.

The liver performs a process called gluconeogenesis — it manufactures glucose and releases it into the bloodstream. This is useful during fasting (it keeps blood sugar from dropping too low overnight), but in people with insulin resistance, the liver often continues releasing glucose even when blood sugar is already elevated. This “run-away gluconeogenesis” is a major driver of high fasting blood sugar.

Metformin suppresses gluconeogenesis. It also activates an enzyme called AMPK, which improves the body’s ability to use insulin — essentially making cells more responsive to the insulin that’s already there.

The result: fasting blood sugar drops, A1C improves, and the pancreas isn’t pushed to produce extra insulin to compensate for elevated glucose. That last point is significant — chronic high insulin levels are associated with weight gain and cardiovascular strain, so drugs that improve insulin sensitivity without increasing insulin secretion have an advantage over some alternatives.

Prediabetes and prevention

Metformin is FDA-approved for type 2 diabetes, not prediabetes. But the data on prediabetes is compelling enough that many physicians prescribe it off-label in that context.

The landmark Diabetes Prevention Program study, which ran from the mid-1990s to 2001, compared metformin, lifestyle intervention, and placebo in over 3,000 people with prediabetes. Lifestyle changes (diet and exercise) reduced diabetes progression by 58%. Metformin reduced it by 31%. Both were significantly better than placebo.

The lifestyle group won, which is worth remembering. But 31% is not nothing — particularly for people who are struggling to make consistent lifestyle changes or who have multiple risk factors.

The longevity research

This is where metformin gets more interesting, and also more speculative.

Epidemiological studies have consistently found that people with type 2 diabetes taking metformin live longer — and in some analyses, longer than matched people without diabetes who are not taking it. That’s a strange finding if metformin were only treating diabetes. It suggests the drug might have effects beyond blood sugar.

The leading hypothesis involves AMPK activation. AMPK is sometimes called a “cellular energy sensor.” When activated, it triggers processes associated with cellular maintenance and longevity — including a form of cellular housekeeping called autophagy. Some researchers believe chronic AMPK activation from metformin may partly explain the apparent longevity benefit.

This has led to the TAME trial (Targeting Aging with Metformin), a large ongoing clinical trial designed to test whether metformin can slow biological aging processes in people without diabetes. Results are expected in the late 2020s.

What this means practically

Metformin is a prescription drug. If you have type 2 diabetes, your doctor has likely already discussed it with you. If you have prediabetes or strong metabolic risk factors and want to know whether it’s appropriate for you, that’s a reasonable conversation to have with your doctor — including the off-label use question.

The side effects are mostly gastrointestinal, particularly at the start. Taking it with food and starting at a lower dose helps. The more serious (but rare) risk is a condition called lactic acidosis, primarily in people with kidney disease.


This content is for educational purposes only and is not medical advice. Consult your healthcare provider before making changes to your diet, supplements, or medications.